Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 12/20 | 0.39 |
| ▸ | CNR1 | P21554 | 3/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 6/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 6/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 6/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13501743 | 0.93 | SLC1A3 (0.41) | CNR2CNR1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL13435110 | 0.85 | SLC1A3 (0.37) | CNR2CNR1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL13499740 | 0.83 | SLC1A3 (0.36) | CNR2CNR1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL13461495 | 0.83 | SLC1A3 (0.36) | CNR2CNR1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL30170355 | 0.81 | SLC1A3 (0.39) | CNR2CNR1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL30170199 | 0.80 | SLC1A3 (0.49) | CNR2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL13435118 | 0.79 | SLC1A3 (0.40) | CNR2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL13499748 | 0.79 | SLC1A3 (0.40) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL13461544 | 0.78 | SLC1A3 (0.39) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL13501744 | 0.77 | SLC1A3 (0.46) | CNR2CNR1SLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655647-B2 | Substituted lactams as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-20100009966-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009966-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BACE1, APP, APH1A | CNR2 4219/4885CNR1 3817/4885SLC1A3 801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.